Valeant Pharmaceuticals International Inc. said that it will buy bankrupt cancer vaccine maker Dendreon Corp. after no additional qualified bids came forward by yesterday’s deadline, Reuters reported. Valeant, of Laval, Quebec, will get Seattle-based Dendreon's Provenge cancer treatment and other assets for $400 million in cash. Dendreon and Valeant will seek court approval of the sale on Feb. 20, Valeant said. It expects to close the deal by the end of this month.
